?

Discussions and Knowledge Gaps

2

Does the cerebellum play a causal role in cervical dystonia, or is its involvement a downstream consequence of network dysfunction elsewhere?

KNOWLEDGE GAP OPEN cd_cerebellar_contribution

Attached to

pathophysiology#Sensorimotor Network Dysfunction

The cerebellum is named as a component of the dystonia network and has been repeatedly implicated, but studies testing cerebellar function directly in patients are described as giving equivocal results. That is an unusual position for a structure to occupy: implicated enough to be in every formulation of the network, but not demonstrated well enough for its role to be stated. The question matters because the answer changes what a therapeutic target looks like. If cerebellar dysfunction is causal, it is a target; if it is a downstream consequence of abnormal basal ganglia output, modulating it would be treating a symptom of a symptom.

Proposed experiments

Cerebellar function testing stratified by phenotype and disease duration

cd_cerebellar_function_stratified

Test cerebellar function in cervical dystonia patients stratified by duration, presence of dystonic tremor, and sensory-trick responsiveness, rather than as one group. Equivocal group-level results are what you expect if a real effect is present in a subgroup, so the stratification is the experiment.

How does a light sensory stimulus transiently abolish an involuntary motor output in cervical dystonia?

OPEN QUESTION OPEN cd_sensory_trick_mechanism

Attached to

pathophysiology#Disordered Sensorimotor Integration

The sensory trick is the most mechanistically informative phenomenon in the disease and the least explained. Touching the chin or cheek can abolish the dystonic posture within moments, and the effect is often lost as the disease progresses. Any complete account of cervical dystonia has to explain why an afferent signal that carries no mechanical force can switch off a sustained motor output, and why that capacity decays. The phenomenon is the strongest bedside argument that the fault lies in sensorimotor integration rather than in motor execution, which is why it is curated as a question attached to that node rather than merely listed as a clinical sign.

⚙

Pathophysiology

3

Sensorimotor Network Dysfunction

The primary abnormality, and it is distributed rather than focal. Dystonia is understood as a disorder of a network spanning basal ganglia, thalamus, sensorimotor cortex and cerebellum, in which no single structure is lesioned and the pathology lies in how they operate together. This node is stated at network scale deliberately: assigning the fault to one structure would claim more than the evidence supports, and decades of attempts to localise it are why the network formulation exists.

Downstream

Disordered Sensorimotor Integration The specific functional consequence for which there is direct clinical evidence at the bedside.

Involuntary Sustained Neck Muscle Contraction The motor output of the disordered network.

Anxiety Drawn from the network node rather than from the motor node deliberately. The cited source states that the non-motor symptoms cannot be attributed to the motor symptoms as a secondary consequence, which rules out the obvious route, distress at a visible posture, and leaves the shared network as the candidate origin. The intermediates are unknown and the edge says so.

Depression Same reasoning as the anxiety edge, and resting on the same statement that the non-motor burden is not secondary to the movement disorder.

Show evidence (2 references)

PMID:33795752 SUPPORT Human Clinical

"Dystonia is conceptualized as a network disorder involving basal ganglia, thalamus, sensorimotor cortex and the cerebellum."

States the network formulation and names its four components, which is exactly the scope at which this node is pitched.

PMID:37738511 SUPPORT Human Clinical

"Dystonia is a clinically and genetically highly heterogeneous neurological disorder characterized by abnormal movements and postures caused by involuntary sustained or intermittent muscle contractions."

Defines the disorder at the level of the movement abnormality and records that it is heterogeneous both clinically and genetically, which is the reason a single mechanism is not asserted.

Disordered Sensorimotor Integration

Abnormal processing of sensory information in the service of movement, rather than a purely efferent motor fault. The clinical evidence for this is unusually direct and unusually strange: a light touch to the chin or cheek can transiently abolish the dystonic posture. A sensory input that switches off an involuntary motor output is difficult to explain if the lesion is downstream of the motor command, and it is the single most informative sign in the disease.

Downstream

Involuntary Sustained Neck Muscle Contraction Faulty integration produces the abnormal sustained motor output.

Show evidence (2 references)

PMID:37738511 SUPPORT Human Clinical

"The geste antagoniste (also known as the sensory trick) describes a voluntary action by the patient that can reduce or even completely suppress abnormal postures or dystonic movements, for example, touching the chin in cervical dystonia."

The direct evidence for this node. A voluntary sensory action that completely suppresses an involuntary motor output is the phenomenon that makes sensorimotor integration, rather than motor execution, the right framing, and the source names cervical dystonia specifically.

PMID:33795752 SUPPORT Human Clinical

"Dystonia is conceptualized as a network disorder involving basal ganglia, thalamus, sensorimotor cortex and the cerebellum."

Places sensorimotor cortex and cerebellum in the network whose dysfunction this node describes.

Involuntary Sustained Neck Muscle Contraction

Sustained or intermittent co-contraction of cervical muscles, including inappropriate activation of antagonists, producing abnormal head posture and frequently a dystonic tremor. The muscles themselves are normal, which is why treatment aimed at them is symptomatic: the fault is in the command, not the effector.

Downstream

Torticollis The abnormal head posture itself.

Neck pain Sustained contraction against antagonists is painful in the majority of patients.

Tremor Dystonic tremor accompanies the posture in a substantial minority.

Show evidence (1 reference)

PMID:33180963 SUPPORT Human Clinical

"Cervical dystonia is the most common form of focal dystonia, and is a highly disabling movement disorder, characterised by involuntary, usually painful, head posturing."

States the motor phenomenon, that it is involuntary, that it is usually painful, and that the resulting disability is substantial.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

5

Nervous System 3

Tremor HP:0001337

No frequency band is asserted, and the reason is worth stating because the number is tempting. The registry table reports tremor in 516 of 1701, which is 30.3 per cent, but that denominator is every patient with idiopathic adult-onset dystonia of any distribution. The same table gives CD-specific rows where it means CD, quoting neck pain in cervical dystonia against a denominator of 848, so the absence of a CD row for tremor is informative rather than accidental. A band derived from the all-dystonia figure would be a claim about cervical dystonia that this source does not make.

Show evidence (1 reference)

PMID:38429083 SUPPORT INDIRECT Human Clinical

"Women and men were characterised by a similar proportion of sensory trick, eye symptoms in blepharospasm (BSP), neck pain in cervical dystonia (CD) and family history of dystonia or tremor; tremors in the neck and/or in the upper limb tended to be more frequent in women than in men, but the..."

Establishes that tremor of the neck is a recorded feature in this dystonia cohort, which supports the phenotype existing. Graded INDIRECT because the sentence is about a sex comparison and the study's tremor denominator is all adult-onset dystonia rather than cervical dystonia, so it reaches this entry through the wider cohort. No frequency is derived from it.

Anxiety HP:0000739

Show evidence (1 reference)

PMID:21484874 SUPPORT Human Clinical

"Non-motor symptoms include alterations of mood, cognition, sleep, autonomic function and/or pain which cannot be directly attributed as a secondary consequence of motor symptoms."

States both the range of non-motor symptoms and, decisively, that they cannot be attributed simply to the motor disorder.

Depression HP:0000716

Show evidence (1 reference)

PMID:21484874 SUPPORT Human Clinical

"Non-motor symptoms include alterations of mood, cognition, sleep, autonomic function and/or pain which cannot be directly attributed as a secondary consequence of motor symptoms."

Includes alterations of mood among the non-motor symptoms that are not secondary to motor disability.

Other 2

Torticollis HP:0000473

Onset: ADULT

Show evidence (1 reference)

PMID:33180963 SUPPORT Human Clinical

"Cervical dystonia is the most common form of focal dystonia, and is a highly disabling movement disorder, characterised by involuntary, usually painful, head posturing."

Names the head posturing that defines this phenotype and records its involuntary character.

Neck pain FREQUENT HP:0030833

Show evidence (2 references)

PMID:33180963 SUPPORT Human Clinical

"Cervical dystonia is the most common form of focal dystonia, and is a highly disabling movement disorder, characterised by involuntary, usually painful, head posturing."

The word "usually" in a definitional sentence supports the FREQUENT band of 30 to 79 per cent for pain in this disease.

PMID:38429083 SUPPORT Human Clinical

"Neck pain in cervical dystonia 488/848 (57.5%)"

Quantifies the band: 488 of 848 patients with cervical dystonia in the registry, 57.5 per cent, which sits squarely in FREQUENT.

🧬

Genetic Associations

4

THAP1

Gene: THAP1 hgnc:20856 relationship_type: SUSCEPTIBILITY

GNAL

Gene: GNAL hgnc:4388 relationship_type: SUSCEPTIBILITY

ANO3

Gene: ANO3 hgnc:14004 relationship_type: SUSCEPTIBILITY

Polygenic and multifactorial susceptibility

relationship_type: SUSCEPTIBILITY

Show evidence (2 references)

PMID:37445923 SUPPORT Human Clinical

"Assessment of 30 CD- and BSP-associated genes from 121 patients revealed a total of 209 different heterozygous variants in 24 genes."

Establishes the scale of variation found by panel sequencing, which is the denominator against which the relevant findings must be read.

PMID:37445923 SUPPORT Human Clinical

"Established clinical and genetic validity was determined for nine heterozygous variations (three likely pathogenic and six variants of uncertain significance)."

Nine relevant variants from 209, of which only three were likely pathogenic, is the quantitative basis for treating these genes as contributors in a minority rather than as causes of the common disease.

💊

Medical Actions

2

Botulinum Toxin Type A

Action: Pharmacotherapy NCIT:C15986

Agent: botulinum toxin type A CHEBI:3160

First-line treatment, and mechanistically instructive for where it acts. Injected into the overactive muscles, it cleaves the SNARE machinery required for acetylcholine release at the neuromuscular junction, weakening the muscle that the disordered network is commanding. It therefore works at the far end of the chain, downstream of everything this entry models as the actual pathophysiology, which is precisely why it is effective, why it must be repeated as terminals recover, and why it modifies nothing.

Mechanism Target:

INHIBITS Involuntary Sustained Neck Muscle Contraction — Blocks neuromuscular transmission in the injected muscles, preventing the contraction from being executed without addressing the command that produces it.

Show evidence (1 reference)

PMID:33180963 SUPPORT Human Clinical

"Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition."

Establishes the agent's first-line position for this specific condition.

Show evidence (2 references)

PMID:33180963 SUPPORT Human Clinical

"Overall, both participants and clinicians reported an improvement of subjective clinical status."

The efficacy finding from a Cochrane review, reported as improvement in subjective clinical status by both patients and clinicians.

PMID:33180963 SUPPORT Human Clinical

"We found no evidence supporting the existence of a clear dose-response relationship between BtA and improvement in cervical dystonia-specific impairment, a destinction between BtA formulations, or a variation with use of EMG-guided injection for efficacy outcomes."

Included deliberately as a limit on the treatment rather than as a claim for its efficacy, which the sibling item carries. A first-line therapy without a demonstrable dose-response relationship is one whose optimal dosing cannot be derived from the evidence, which is a real constraint on practice.

Deep Brain Stimulation

Action: Deep Brain Stimulation NCIT:C21024

Pallidal stimulation for disease refractory to botulinum toxin. Unlike injection it acts within the dysfunctional network rather than at its output, which is what makes it interesting mechanistically as well as clinically.

Mechanism Target:

MODULATES Sensorimotor Network Dysfunction — Modulates activity within the basal ganglia component of the network rather than blocking its output, which is the mechanistic distinction from botulinum toxin.

Show evidence (1 reference)

PMID:33795752 SUPPORT Human Clinical

"Dystonia is conceptualized as a network disorder involving basal ganglia, thalamus, sensorimotor cortex and the cerebellum."

Establishes that the basal ganglia are part of the network this treatment targets, which is the rationale for the target. This source is not a trial of stimulation, so it evidences the target and not the efficacy; the efficacy evidence is on the treatment itself.

Show evidence (2 references)

PMID:38823054 SUPPORT Human Clinical

"The mean total BFMDRS motor scores at the 3 different time points were 13.3 ± 9.4 preoperatively, 5.0 ± 4.7 (55.3% improvement, p < 0.001) at 6 months, and 4.5 ± 3.6 (56.6% improvement, p < 0.001) at last follow-up."

Quantifies the effect on a validated dystonia rating scale and, more usefully, shows the six-month improvement is essentially held at a mean follow-up of three years. Durability is the question that matters for an implanted device.

PMID:38823054 SUPPORT Human Clinical

"The outcomes were deemed poor in 6 individuals."

Carried as a limit on the treatment rather than as a claim for it. Six of 24 patients did poorly, which is a quarter of an already refractory cohort, and the paper's own title asks whether the pallidum is the right target at all.

📊

Prevalence

2

Adults, idiopathic adult-onset isolated dystonia

Point Prevalence 30.9 per 100,000 1–9 per 10,000

Reported prevalence estimates for isolated dystonia of around 30.9 and 52.7 per 100,000, recorded here at the lower figure. Both are widely regarded as underestimates because the disorder is frequently undiagnosed or misdiagnosed, often for years, and because ascertainment depends on referral to a movement disorder service. Cervical dystonia is the commonest focal form, so it accounts for a substantial share of this total rather than being additional to it.

Show evidence (2 references)

PMID:37738511 SUPPORT Human Clinical

"According to recent epidemiological studies, the prevalence of isolated dys- tonia may be a bit higher and was estimated as 52.7/100,000 ( 7) or 30.9/100,000 (8)."

The source of the recorded rate. Note carefully what it measures: this is the prevalence of ISOLATED DYSTONIA as a whole, not of cervical dystonia specifically, and the same sentence offers a second estimate of 30.9 per 100,000. The lower figure is recorded in this entry as the conservative choice.

PMID:37445923 SUPPORT Human Clinical

"The two most common forms of adult-onset focal dystonia are cervical dystonia (CD) and benign essential blepharospasm (BSP)."

Establishes cervical dystonia as one of the two commonest adult-onset focal dystonias, which is the basis for treating it as a major component of the isolated dystonia prevalence above rather than a minor one.

Adults, sex distribution

Unknown Unknown

Women predominate in cervical dystonia, with reported female-to-male ratios close to two. Recorded with measure_type UNKNOWN rather than POINT_PREVALENCE because a sex ratio is not a prevalence measure at all: it describes the composition of the affected population rather than its size, and forcing it into a prevalence slot would misrepresent what was measured. The predominance is not general to dystonia: it reverses in task-specific upper limb dystonia, which argues that it reflects something about craniocervical forms specifically rather than a general ascertainment bias toward women.

Show evidence (1 reference)

PMID:38429083 SUPPORT Human Clinical

"Women predominated over men in blepharospasm, oromandibular, laryngeal and cervical dystonia; the sex ratio was reversed in task-specific upper limb dystonia; and no clear sex difference emerged in non-task-specific upper limb dystonia and lower limb dystonia."

Gives both the female predominance in cervical dystonia and its reversal in task-specific limb dystonia, which together are what make this a finding about the disease rather than about who seeks care.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Cervical Dystonia:

Monogenic and syndromic dystonias

Overlapping Features Cervical involvement occurs within defined genetic disorders, including dopa-responsive dystonia, myoclonus-dystonia, and the dystonia-parkinsonism syndromes, all separately curated in this knowledge base. The distinction matters practically: dopa-responsive dystonia in particular is treatable in a way this disease is not, so it must be excluded rather than assumed absent.

Secondary and acquired torticollis

Overlapping Features Abnormal head posture from structural, ocular, vestibular, infectious or drug-induced causes, including tardive dystonia after dopamine receptor blockade. Distinguished by history, by the absence of a sensory trick, and by the presence of an identifiable cause.

Essential tremor with head involvement

Overlapping Features Head tremor without sustained abnormal posture. The distinction can be genuinely difficult when dystonic tremor is prominent and the posture is subtle, and it turns on whether a sustained directional pull is present between tremor beats.

{ }

Source YAML

click to show

name: Cervical Dystonia
creation_date: "2026-08-16T00:00:00Z"
description: >-
  Cervical dystonia is the commonest focal dystonia: sustained or intermittent
  involuntary contraction of neck muscles pulling the head into abnormal
  postures, typically beginning in the fifth decade and usually painful. It is
  disabling out of proportion to how localised it looks, because the neck cannot
  be rested and the posture cannot be hidden.

  The honest mechanistic statement is that this is a network disorder rather than
  a lesion. No single structure is damaged. Dysfunction is distributed across
  basal ganglia, thalamus, sensorimotor cortex and cerebellum, and the entry
  models it that way rather than assigning a locus the evidence does not support.
  The cerebellar contribution in particular is real but contested: it has been
  repeatedly implicated and studies testing cerebellar function in patients have
  given equivocal results, which is curated as an open question rather than
  resolved in either direction.

  Two features distinguish it clinically and both are mechanistically
  informative. The sensory trick, or geste antagoniste, is the phenomenon in
  which lightly touching the chin or cheek transiently abolishes the posture,
  which is difficult to reconcile with a purely motor efferent fault and points
  toward disordered sensorimotor integration. And the non-motor burden, in
  particular pain, anxiety and depression, is substantial and not simply
  secondary to the posture, being reported at rates that track body image and
  attitude rather than objective motor severity.

  Botulinum toxin injected into the overactive muscles is first-line treatment
  and works far downstream of the actual problem, at the neuromuscular junction,
  which is why it is effective, temporary, and not disease-modifying.
category: Complex
disease_term:
  preferred_term: Cervical Dystonia
  term:
    id: MONDO:0000481
    label: cervical dystonia
synonyms:
- Spasmodic torticollis
- Idiopathic cervical dystonia
- Adult-onset focal cervical dystonia
notes: >-
  Scope. This entry covers idiopathic adult-onset focal cervical dystonia, the
  common sporadic form. It is deliberately distinct from the monogenic dystonias
  already curated in this knowledge base, including the dopa-responsive
  dystonias, myoclonus-dystonia, and the dystonia-parkinsonism syndromes, in
  which cervical involvement may occur as one feature of a defined genetic
  disease. Cervical dystonia appearing as a feature of those disorders is not
  this entry.

  Mechanism deliberately under-localised. Dystonia is curated here as a network
  disorder because that is what the evidence supports; no single node claims a
  causal lesion in a specific structure. The cerebellar arm is recorded as an
  open question rather than asserted, because the same source that names the
  network describes cerebellar findings in patients as equivocal.

  Genetics deliberately under-asserted. Most adult-onset isolated cervical
  dystonia is sporadic and multifactorial. Sequencing panels of the associated
  genes return a low diagnostic yield in unselected focal-dystonia cohorts, and
  the entry records that yield rather than implying that these genes explain the
  common disease.

  Provider note. Built from an Edison Falcon deep-research report, which cites by
  DOI and internal corpus keys rather than PMIDs, so all cited DOIs were resolved
  to PubMed records and evidence verified against those. Three of the report's
  suggested HPO identifiers were wrong and were corrected against the ontology:
  it gave HP:0002418 for torticollis (that identifier is Abnormal midbrain
  morphology; correct is HP:0000473), HP:0001336 for tremor (that is Myoclonus;
  correct is HP:0001337), and HP:0003577 for adult onset (that is Congenital
  onset; correct is HP:0003581). Every ontology term in this entry was verified
  independently rather than taken from the report.
pathophysiology:
- name: Sensorimotor Network Dysfunction
  biological_scale: ORGANISM
  description: >-
    The primary abnormality, and it is distributed rather than focal. Dystonia is
    understood as a disorder of a network spanning basal ganglia, thalamus,
    sensorimotor cortex and cerebellum, in which no single structure is lesioned
    and the pathology lies in how they operate together. This node is stated at
    network scale deliberately: assigning the fault to one structure would claim
    more than the evidence supports, and decades of attempts to localise it are
    why the network formulation exists.
  evidence:
  - reference: PMID:33795752
    reference_title: "Motor learning deficits in cervical dystonia point to defective basal ganglia circuitry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystonia is conceptualized as a network disorder involving basal ganglia, thalamus, sensorimotor cortex and the cerebellum."
    explanation: >-
      States the network formulation and names its four components, which is
      exactly the scope at which this node is pitched.
  - reference: PMID:37738511
    reference_title: "Genetics and Pathogenesis of Dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystonia is a clinically and genetically highly heterogeneous neurological disorder characterized by abnormal movements and postures caused by involuntary sustained or intermittent muscle contractions."
    explanation: >-
      Defines the disorder at the level of the movement abnormality and records
      that it is heterogeneous both clinically and genetically, which is the
      reason a single mechanism is not asserted.
  downstream:
  - target: Disordered Sensorimotor Integration
    causal_link_type: DIRECT
    description: >-
      The specific functional consequence for which there is direct clinical
      evidence at the bedside.
  - target: Involuntary Sustained Neck Muscle Contraction
    causal_link_type: DIRECT
    description: >-
      The motor output of the disordered network.
  - target: Anxiety
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Drawn from the network node rather than from the motor node deliberately.
      The cited source states that the non-motor symptoms cannot be attributed to
      the motor symptoms as a secondary consequence, which rules out the obvious
      route, distress at a visible posture, and leaves the shared network as the
      candidate origin. The intermediates are unknown and the edge says so.
  - target: Depression
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Same reasoning as the anxiety edge, and resting on the same statement that
      the non-motor burden is not secondary to the movement disorder.
- name: Disordered Sensorimotor Integration
  biological_scale: ORGANISM
  description: >-
    Abnormal processing of sensory information in the service of movement, rather
    than a purely efferent motor fault. The clinical evidence for this is
    unusually direct and unusually strange: a light touch to the chin or cheek
    can transiently abolish the dystonic posture. A sensory input that switches
    off an involuntary motor output is difficult to explain if the lesion is
    downstream of the motor command, and it is the single most informative sign
    in the disease.
  evidence:
  - reference: PMID:37738511
    reference_title: "Genetics and Pathogenesis of Dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The geste antagoniste (also known as the sensory trick) describes a voluntary action by the patient that can reduce or even completely suppress abnormal postures or dystonic movements, for example, touching the chin in cervical dystonia."
    explanation: >-
      The direct evidence for this node. A voluntary sensory action that
      completely suppresses an involuntary motor output is the phenomenon that
      makes sensorimotor integration, rather than motor execution, the right
      framing, and the source names cervical dystonia specifically.
  - reference: PMID:33795752
    reference_title: "Motor learning deficits in cervical dystonia point to defective basal ganglia circuitry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dystonia is conceptualized as a network disorder involving basal ganglia, thalamus, sensorimotor cortex and the cerebellum."
    explanation: >-
      Places sensorimotor cortex and cerebellum in the network whose dysfunction
      this node describes.
  downstream:
  - target: Involuntary Sustained Neck Muscle Contraction
    causal_link_type: DIRECT
    description: >-
      Faulty integration produces the abnormal sustained motor output.
- name: Involuntary Sustained Neck Muscle Contraction
  biological_scale: TISSUE
  description: >-
    Sustained or intermittent co-contraction of cervical muscles, including
    inappropriate activation of antagonists, producing abnormal head posture and
    frequently a dystonic tremor. The muscles themselves are normal, which is why
    treatment aimed at them is symptomatic: the fault is in the command, not the
    effector.
  evidence:
  - reference: PMID:33180963
    reference_title: "Botulinum toxin type A therapy for cervical dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical dystonia is the most common form of focal dystonia, and is a highly disabling movement disorder, characterised by involuntary, usually painful, head posturing."
    explanation: >-
      States the motor phenomenon, that it is involuntary, that it is usually
      painful, and that the resulting disability is substantial.
  downstream:
  - target: Torticollis
    causal_link_type: DIRECT
    description: >-
      The abnormal head posture itself.
  - target: Neck pain
    causal_link_type: DIRECT
    description: >-
      Sustained contraction against antagonists is painful in the majority of
      patients.
  - target: Tremor
    causal_link_type: DIRECT
    description: >-
      Dystonic tremor accompanies the posture in a substantial minority.
phenotypes:
- name: Torticollis
  category: Neurological
  description: >-
    Abnormal head and neck posture from involuntary muscle contraction, the
    defining feature. Direction varies between patients and may combine rotation,
    tilt, flexion and extension.
  phenotype_term:
    preferred_term: Torticollis
    term:
      id: HP:0000473
      label: Torticollis
    onset:
      onset_category: ADULT
      notes: >-
        Onset is characteristically in adulthood, typically the fifth decade,
        which is part of what distinguishes idiopathic focal cervical dystonia
        from the childhood-onset monogenic dystonias.
  evidence:
  - reference: PMID:33180963
    reference_title: "Botulinum toxin type A therapy for cervical dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical dystonia is the most common form of focal dystonia, and is a highly disabling movement disorder, characterised by involuntary, usually painful, head posturing."
    explanation: >-
      Names the head posturing that defines this phenotype and records its
      involuntary character.
- name: Neck pain
  category: Neurological
  description: >-
    Pain in the affected muscles, present in the majority and a major contributor
    to disability. It is described in the defining literature as a usual rather
    than occasional accompaniment, which is worth noting because pain is
    sometimes treated as a secondary complaint in movement disorders.
  phenotype_term:
    preferred_term: Neck pain
    term:
      id: HP:0030833
      label: Neck pain
  frequency: FREQUENT
  evidence:
  - reference: PMID:33180963
    reference_title: "Botulinum toxin type A therapy for cervical dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cervical dystonia is the most common form of focal dystonia, and is a highly disabling movement disorder, characterised by involuntary, usually painful, head posturing."
    explanation: >-
      The word "usually" in a definitional sentence supports the FREQUENT band of
      30 to 79 per cent for pain in this disease.
  - reference: PMID:38429083
    reference_title: "Does sex influence the natural history of idiopathic adult-onset dystonia?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neck pain in cervical dystonia 488/848 (57.5%)"
    explanation: >-
      Quantifies the band: 488 of 848 patients with cervical dystonia in the
      registry, 57.5 per cent, which sits squarely in FREQUENT.
- name: Tremor
  category: Neurological
  description: >-
    Dystonic head tremor accompanying the posture in a substantial minority. It
    is distinguished from essential tremor by its association with the dystonic
    posture and by its tendency to worsen when the head is moved away from the
    direction of pull.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  notes: >-
    No frequency band is asserted, and the reason is worth stating because the
    number is tempting. The registry table reports tremor in 516 of 1701, which
    is 30.3 per cent, but that denominator is every patient with idiopathic
    adult-onset dystonia of any distribution. The same table gives CD-specific
    rows where it means CD, quoting neck pain in cervical dystonia against a
    denominator of 848, so the absence of a CD row for tremor is informative
    rather than accidental. A band derived from the all-dystonia figure would
    be a claim about cervical dystonia that this source does not make.
  evidence:
  - reference: PMID:38429083
    reference_title: "Does sex influence the natural history of idiopathic adult-onset dystonia?"
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women and men were characterised by a similar proportion of sensory trick, eye symptoms in blepharospasm (BSP), neck pain in cervical dystonia (CD) and family history of dystonia or tremor; tremors in the neck and/or in the upper limb tended to be more frequent in women than in men, but the difference did not reach the level of statistical significance after Bonferroni correction (p=0.05/5=0.01) (table 2)."
    explanation: >-
      Establishes that tremor of the neck is a recorded feature in this dystonia
      cohort, which supports the phenotype existing. Graded INDIRECT because the
      sentence is about a sex comparison and the study's tremor denominator is
      all adult-onset dystonia rather than cervical dystonia, so it reaches this
      entry through the wider cohort. No frequency is derived from it.
- name: Anxiety
  category: Psychiatric
  description: >-
    Anxiety and social phobia occur at rates that are not explained by motor
    severity alone. The non-motor burden of this disease is substantial and is
    explicitly described as not reducible to a secondary consequence of the
    movement disorder, which matters because it is easy to assume that a visible
    postural disorder causes distress purely by being visible.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:21484874
    reference_title: "Nonmotor manifestations of dystonia: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-motor symptoms include alterations of mood, cognition, sleep, autonomic function and/or pain which cannot be directly attributed as a secondary consequence of motor symptoms."
    explanation: >-
      States both the range of non-motor symptoms and, decisively, that they
      cannot be attributed simply to the motor disorder.
- name: Depression
  category: Psychiatric
  description: >-
    Depressed mood, part of the same non-motor burden and likewise not simply a
    reaction to disability.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:21484874
    reference_title: "Nonmotor manifestations of dystonia: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Non-motor symptoms include alterations of mood, cognition, sleep, autonomic function and/or pain which cannot be directly attributed as a secondary consequence of motor symptoms."
    explanation: >-
      Includes alterations of mood among the non-motor symptoms that are not
      secondary to motor disability.
genetic:
- name: THAP1
  gene_term:
    preferred_term: THAP1
    term:
      id: hgnc:20856
      label: THAP1
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Recurrently implicated in focal dystonia screening cohorts. Bound so it is
    queryable, and typed SUSCEPTIBILITY rather than CAUSATIVE because in the
    common adult-onset sporadic disease these genes explain a small minority; see
    the yield figures on the susceptibility record below.
- name: GNAL
  gene_term:
    preferred_term: GNAL
    term:
      id: hgnc:4388
      label: GNAL
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Implicated in adult-onset focal and segmental dystonia, with craniocervical
    predominance. Typed SUSCEPTIBILITY for the same reason as THAP1.
- name: ANO3
  gene_term:
    preferred_term: ANO3
    term:
      id: hgnc:14004
      label: ANO3
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Implicated in craniocervical dystonia. Typed SUSCEPTIBILITY for the same
    reason as the others.
- name: Polygenic and multifactorial susceptibility
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Most adult-onset isolated cervical dystonia is sporadic and multifactorial. A
    set of genes recurs in screening studies of focal dystonia cohorts, including
    THAP1, GNAL and ANO3, but they explain a small minority of unselected cases.
    A 30-gene panel applied to a focal dystonia cohort found many heterozygous
    variants and very few that were clinically and genetically relevant, which is
    the honest summary of where genetic testing currently stands in the common
    disease. No causal gene is bound at the disease level for that reason.
  evidence:
  - reference: PMID:37445923
    reference_title: "Genetic Screening of a Hungarian Cohort with Focal Dystonia Identified Several Novel Putative Pathogenic Gene Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Assessment of 30 CD- and BSP-associated genes from 121 patients revealed a total of 209 different heterozygous variants in 24 genes."
    explanation: >-
      Establishes the scale of variation found by panel sequencing, which is the
      denominator against which the relevant findings must be read.
  - reference: PMID:37445923
    reference_title: "Genetic Screening of a Hungarian Cohort with Focal Dystonia Identified Several Novel Putative Pathogenic Gene Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Established clinical and genetic validity was determined for nine heterozygous variations (three likely pathogenic and six variants of uncertain significance)."
    explanation: >-
      Nine relevant variants from 209, of which only three were likely
      pathogenic, is the quantitative basis for treating these genes as
      contributors in a minority rather than as causes of the common disease.
treatments:
- name: Botulinum Toxin Type A
  description: >-
    First-line treatment, and mechanistically instructive for where it acts.
    Injected into the overactive muscles, it cleaves the SNARE machinery required
    for acetylcholine release at the neuromuscular junction, weakening the muscle
    that the disordered network is commanding. It therefore works at the far end
    of the chain, downstream of everything this entry models as the actual
    pathophysiology, which is precisely why it is effective, why it must be
    repeated as terminals recover, and why it modifies nothing.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: botulinum toxin type A
      term:
        id: CHEBI:3160
        label: Botulinum toxin type A
  target_mechanisms:
  - target: Involuntary Sustained Neck Muscle Contraction
    treatment_effect: INHIBITS
    description: >-
      Blocks neuromuscular transmission in the injected muscles, preventing the
      contraction from being executed without addressing the command that
      produces it.
    evidence:
    - reference: PMID:33180963
      reference_title: "Botulinum toxin type A therapy for cervical dystonia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition."
      explanation: >-
        Establishes the agent's first-line position for this specific condition.
  evidence:
  - reference: PMID:33180963
    reference_title: "Botulinum toxin type A therapy for cervical dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, both participants and clinicians reported an improvement of subjective clinical status."
    explanation: >-
      The efficacy finding from a Cochrane review, reported as improvement in
      subjective clinical status by both patients and clinicians.
  - reference: PMID:33180963
    reference_title: "Botulinum toxin type A therapy for cervical dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found no evidence supporting the existence of a clear dose-response relationship between BtA and improvement in cervical dystonia-specific impairment, a destinction between BtA formulations, or a variation with use of EMG-guided injection for efficacy outcomes."
    explanation: >-
      Included deliberately as a limit on the treatment rather than as a claim
      for its efficacy, which the sibling item carries. A first-line therapy
      without a demonstrable dose-response relationship is one whose optimal
      dosing cannot be derived from the evidence, which is a real constraint on
      practice.
  notes: >-
    The same review found no evidence distinguishing between formulations, and
    none that electromyographic guidance improved efficacy outcomes. Both are
    recorded here because they are frequently assumed in practice.
- name: Deep Brain Stimulation
  description: >-
    Pallidal stimulation for disease refractory to botulinum toxin. Unlike
    injection it acts within the dysfunctional network rather than at its output,
    which is what makes it interesting mechanistically as well as clinically.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: Deep Brain Stimulation
    term:
      id: NCIT:C21024
      label: Deep Brain Stimulation
  target_mechanisms:
  - target: Sensorimotor Network Dysfunction
    treatment_effect: MODULATES
    description: >-
      Modulates activity within the basal ganglia component of the network rather
      than blocking its output, which is the mechanistic distinction from
      botulinum toxin.
    evidence:
    - reference: PMID:33795752
      reference_title: "Motor learning deficits in cervical dystonia point to defective basal ganglia circuitry."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dystonia is conceptualized as a network disorder involving basal ganglia, thalamus, sensorimotor cortex and the cerebellum."
      explanation: >-
        Establishes that the basal ganglia are part of the network this treatment
        targets, which is the rationale for the target. This source is not a
        trial of stimulation, so it evidences the target and not the efficacy;
        the efficacy evidence is on the treatment itself.
  evidence:
  - reference: PMID:38823054
    reference_title: "Long-term follow-up of pallidal deep brain stimulation for craniocervical dystonia: is the globus pallidus internus the best target?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean total BFMDRS motor scores at the 3 different time points were 13.3 ± 9.4 preoperatively, 5.0 ± 4.7 (55.3% improvement, p < 0.001) at 6 months, and 4.5 ± 3.6 (56.6% improvement, p < 0.001) at last follow-up."
    explanation: >-
      Quantifies the effect on a validated dystonia rating scale and, more
      usefully, shows the six-month improvement is essentially held at a mean
      follow-up of three years. Durability is the question that matters for an
      implanted device.
  - reference: PMID:38823054
    reference_title: "Long-term follow-up of pallidal deep brain stimulation for craniocervical dystonia: is the globus pallidus internus the best target?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The outcomes were deemed poor in 6 individuals."
    explanation: >-
      Carried as a limit on the treatment rather than as a claim for it. Six of
      24 patients did poorly, which is a quarter of an already refractory
      cohort, and the paper's own title asks whether the pallidum is the right
      target at all.
  notes: >-
    The efficacy evidence here is a single-centre series of 24 patients with
    refractory craniocervical dystonia, which is not cervical dystonia alone and
    not a controlled trial, so the improvement figures describe this cohort
    rather than establishing an effect size.
discussions:
- discussion_id: cd_cerebellar_contribution
  prompt: >-
    Does the cerebellum play a causal role in cervical dystonia, or is its
    involvement a downstream consequence of network dysfunction elsewhere?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Sensorimotor Network Dysfunction
  rationale: >-
    The cerebellum is named as a component of the dystonia network and has been
    repeatedly implicated, but studies testing cerebellar function directly in
    patients are described as giving equivocal results. That is an unusual
    position for a structure to occupy: implicated enough to be in every
    formulation of the network, but not demonstrated well enough for its role to
    be stated. The question matters because the answer changes what a therapeutic
    target looks like. If cerebellar dysfunction is causal, it is a target; if it
    is a downstream consequence of abnormal basal ganglia output, modulating it
    would be treating a symptom of a symptom.
  proposed_experiments:
  - experiment_id: cd_cerebellar_function_stratified
    name: Cerebellar function testing stratified by phenotype and disease duration
    description: >-
      Test cerebellar function in cervical dystonia patients stratified by
      duration, presence of dystonic tremor, and sensory-trick responsiveness,
      rather than as one group. Equivocal group-level results are what you expect
      if a real effect is present in a subgroup, so the stratification is the
      experiment.
- discussion_id: cd_sensory_trick_mechanism
  prompt: >-
    How does a light sensory stimulus transiently abolish an involuntary motor
    output in cervical dystonia?
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - pathophysiology#Disordered Sensorimotor Integration
  rationale: >-
    The sensory trick is the most mechanistically informative phenomenon in the
    disease and the least explained. Touching the chin or cheek can abolish the
    dystonic posture within moments, and the effect is often lost as the disease
    progresses. Any complete account of cervical dystonia has to explain why an
    afferent signal that carries no mechanical force can switch off a sustained
    motor output, and why that capacity decays. The phenomenon is the strongest
    bedside argument that the fault lies in sensorimotor integration rather than
    in motor execution, which is why it is curated as a question attached to that
    node rather than merely listed as a clinical sign.
differential_diagnoses:
- name: Monogenic and syndromic dystonias
  description: >-
    Cervical involvement occurs within defined genetic disorders, including
    dopa-responsive dystonia, myoclonus-dystonia, and the dystonia-parkinsonism
    syndromes, all separately curated in this knowledge base. The distinction
    matters practically: dopa-responsive dystonia in particular is treatable in a
    way this disease is not, so it must be excluded rather than assumed absent.
- name: Secondary and acquired torticollis
  description: >-
    Abnormal head posture from structural, ocular, vestibular, infectious or
    drug-induced causes, including tardive dystonia after dopamine receptor
    blockade. Distinguished by history, by the absence of a sensory trick, and by
    the presence of an identifiable cause.
- name: Essential tremor with head involvement
  description: >-
    Head tremor without sustained abnormal posture. The distinction can be
    genuinely difficult when dystonic tremor is prominent and the posture is
    subtle, and it turns on whether a sustained directional pull is present
    between tremor beats.
prevalence:
- population: Adults, idiopathic adult-onset isolated dystonia
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 30.9
  notes: >-
    Reported prevalence estimates for isolated dystonia of around 30.9 and 52.7
    per 100,000, recorded here at the lower figure. Both are widely regarded as
    underestimates because the disorder is frequently undiagnosed or
    misdiagnosed, often for years, and because ascertainment depends on referral
    to a movement disorder service. Cervical dystonia is the commonest focal
    form, so it accounts for a substantial share of this total rather than being
    additional to it.
  evidence:
  - reference: PMID:37738511
    reference_title: "Genetics and Pathogenesis of Dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "According to recent epidemiological studies, the prevalence of isolated dys- tonia may be a bit higher and was estimated as 52.7/100,000 ( 7) or 30.9/100,000 (8)."
    explanation: >-
      The source of the recorded rate. Note carefully what it measures: this is
      the prevalence of ISOLATED DYSTONIA as a whole, not of cervical dystonia
      specifically, and the same sentence offers a second estimate of 30.9 per
      100,000. The lower figure is recorded in this entry as the conservative
      choice.
  - reference: PMID:37445923
    reference_title: "Genetic Screening of a Hungarian Cohort with Focal Dystonia Identified Several Novel Putative Pathogenic Gene Variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The two most common forms of adult-onset focal dystonia are cervical dystonia (CD) and benign essential blepharospasm (BSP)."
    explanation: >-
      Establishes cervical dystonia as one of the two commonest adult-onset focal
      dystonias, which is the basis for treating it as a major component of the
      isolated dystonia prevalence above rather than a minor one.
- population: Adults, sex distribution
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    Women predominate in cervical dystonia, with reported female-to-male ratios
    close to two. Recorded with measure_type UNKNOWN rather than POINT_PREVALENCE
    because a sex ratio is not a prevalence measure at all: it describes the
    composition of the affected population rather than its size, and forcing it
    into a prevalence slot would misrepresent what was measured.
    The predominance is not general to dystonia: it reverses in task-specific
    upper limb dystonia, which argues that it reflects something about
    craniocervical forms specifically rather than a general ascertainment bias
    toward women.
  evidence:
  - reference: PMID:38429083
    reference_title: "Does sex influence the natural history of idiopathic adult-onset dystonia?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Women predominated over men in blepharospasm, oromandibular, laryngeal and cervical dystonia; the sex ratio was reversed in task-specific upper limb dystonia; and no clear sex difference emerged in non-task-specific upper limb dystonia and lower limb dystonia."
    explanation: >-
      Gives both the female predominance in cervical dystonia and its reversal in
      task-specific limb dystonia, which together are what make this a finding
      about the disease rather than about who seeks care.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Cervical Dystonia: Disease-Characteristics Research Report

Edison Scientific Literature 29 citations 2026-08-16T20:15:59.849147

Cervical Dystonia: Disease-Characteristics Research Report

Scope and evidence note

This report prioritizes 2023–2024 literature retrieved for this review. Cervical-dystonia (CD)-specific human evidence is distinguished from evidence about dystonia generally. Some requested database fields—particularly exact MONDO/Orphanet/HPO accessions, population allele frequencies, and active ClinicalTrials.gov records—could not be independently queried in the available retrieval environment; such fields are marked for ontology-database verification rather than inferred.

Table: This table condenses key cervical dystonia knowledge-base facts across clinical, genetic, mechanistic, diagnostic, therapeutic, prognostic, and model domains. It distinguishes cervical-dystonia-specific evidence from broader dystonia findings and attaches ontology suggestions plus source metadata for downstream curation.

1. Disease information

Definition. Cervical dystonia is a focal dystonia in which sustained or intermittent involuntary contractions of cervical muscles produce patterned, often twisting or repetitive head/neck movements and abnormal postures. It was historically called spasmodic torticollis. Presentations include torticollis, laterocollis/laterocaput, antecollis/antecaput, retrocollis/retrocaput, sagittal or lateral shift, and combinations thereof. Dystonic head tremor, muscle hypertrophy, pain, overflow activation, and a relieving maneuver (“geste antagoniste” or sensory trick, such as touching the chin) support the diagnosis. The current expert framework classifies dystonia on two axes: clinical characteristics—age at onset, distribution, temporal pattern, and associated features—and etiology. “Focal” means one body region; isolated dystonia permits tremor but no other movement disorder. (thomsen2024geneticsandpathogenesis pages 2-4, thomsen2024geneticsandpathogenesis pages 1-2)

Suggested identifiers. ICD-10-CM G24.3 (“spasmodic torticollis”); ICD-11 is within the dystonia/movement-disorder hierarchy; MeSH concepts include Dystonic Disorders and Torticollis. Common synonyms are cervical dystonia, spasmodic torticollis, adult-onset idiopathic cervical dystonia, idiopathic rotational torticollis, and focal neck dystonia. The exact current MONDO and Orphanet accessions should be resolved against the live ontology release before database ingestion; cervical dystonia should not be conflated with generalized “isolated dystonia” or congenital muscular torticollis.

The evidence summarized here is primarily aggregated disease-level evidence from registries, cohorts, reviews, and experimental models—not individual EHR-derived patient data. One important recent source analyzed 1,701 patients from 42 Italian movement-disorder centers using a common specialist protocol. (velucci2024doessexinfluence pages 1-2)

Exact abstract wording from a 2024 authoritative review: “Dystonia is a clinically and genetically highly heterogeneous neurological disorder characterized by abnormal movements and postures caused by involuntary sustained or intermittent muscle contractions.” DOI: https://doi.org/10.1146/annurev-pathmechdis-051122-110756; first online September 22, 2023; issue date January 2024. (thomsen2024geneticsandpathogenesis pages 1-2)

2. Etiology, risk, protective factors, and gene–environment interaction

Most typical adult-onset isolated CD is idiopathic and multifactorial, not a single-gene disorder. Current models invoke a susceptible motor network in which polygenic/developmental factors interact with age-, sex-, and possibly exposure-dependent triggers. Acquired cervical dystonia can follow structural brain injury, neuroleptic or dopamine-blocking drugs, neurodegenerative disease, infection/autoimmunity, or peripheral trauma, but causality for many reported environmental associations remains uncertain. A subacute, rapidly progressive, relapsing, or neurologically complex presentation should prompt investigation for acquired/autoimmune disease rather than classification as idiopathic CD. (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2, thomsen2024geneticsandpathogenesis pages 2-4)

Risk factors supported most consistently: middle or later adult age, female sex, and family history of dystonia or tremor. In the Italian registry, CD had a female:male ratio of 1.9 (95% CI 1.8–2.1) at last examination and 1.9 (1.7–2.0) at onset. Family history of dystonia or tremor occurred in 11.1% across idiopathic adult-onset dystonia, although this was not CD-specific. The authors proposed that age-related sexual dimorphism could reflect interactions between environmental exposures and hormonal/biological factors; this is a hypothesis rather than a proven causal mechanism. (velucci2024doessexinfluence pages 1-2, velucci2024doessexinfluence pages 2-3)

No replicated protective genetic variant, diet, exercise pattern, medication, or exposure has been shown to prevent idiopathic CD. Alcohol may transiently reduce some dystonic symptoms but is not protective and carries dependence risk. Smoking, diet, exercise, and occupational exposures do not currently support actionable prevention recommendations. No infectious agent is established as the cause of ordinary idiopathic CD.

3. Phenotypes and quality-of-life effects

The principal phenotype is persistent or action-aggravated abnormal head posture with patterned cervical muscle activation. Severity ranges from mild intermittent pulling to fixed, painful postures causing substantial disability. CD usually begins at 45–50 years and generally remains focal, although craniocervical or other segmental spread can occur. (salamon2023geneticscreeningof pages 1-2)

Suggested phenotype annotations include:

Torticollis/abnormal head posture—clinical sign; HPO HP:0002418 (Torticollis) and abnormal head-posture terms.
Dystonia—motor sign; HP:0001332.
Dystonic head tremor—sign; HP:0001336 (Tremor), with a dystonic-tremor qualifier.
Neck pain—symptom; HP:0012531 (Pain) plus neck localization. In the 2024 registry, neck pain affected 488/848 CD cases (57.5%); older systematic-review estimates were 67–75%, illustrating cohort and ascertainment differences. (velucci2024doessexinfluence pages 2-3, kuyper2011nonmotormanifestationsof pages 4-5)
Sensory trick/geste antagoniste—supportive sign; 28.4% across the complete adult-onset dystonia registry, not solely CD. (velucci2024doessexinfluence pages 2-3)
Restricted cervical range of motion, muscle spasm/hypertrophy, dysphagia or dysphonia where relevant—use the corresponding HPO terms after phenotype-level confirmation.
Anxiety, depression, embarrassment, social avoidance, sleep disturbance, and fatigue—nonmotor manifestations requiring separate assessment. An older study summarized in a systematic review found 71% lifetime social phobia among 116 people with spasmodic torticollis, associated more with body image and maladaptive illness attitudes than objective motor severity. (kuyper2011nonmotormanifestationsof pages 4-5)

Pain, visible postural abnormality, tremor, and unpredictable symptom fluctuation interfere with driving, reading, work, sleep, social interaction, and activities of daily living. Motor severity alone therefore incompletely represents quality of life; CD-specific instruments such as the Cervical Dystonia Impact Profile and Toronto Western Spasmodic Torticollis Rating Scale should be complemented by pain, mood, sleep, and participation measures.

4. Genetic and molecular information

CD is genetically heterogeneous. Confirmed monogenic dystonias that can include prominent cervical or craniocervical involvement include THAP1, GNAL, ANO3, TOR1A, and in selected complex or early-onset cases KMT2B, VPS16, SGCE, ADCY5, ATP1A3, GCH1, EIF2AK2, PRKRA, among others. The 2024 review listed 52 well-supported monogenic dystonia genes in the 2022 MDS nomenclature update, while more than 400 genes had been associated with dystonia or dystonic symptoms at varying evidence levels. This broader number must not be interpreted as 400 established CD genes. (thomsen2024geneticsandpathogenesis pages 2-4, thomsen2024geneticsandpathogenesis pages 1-2)

In a 2023 Hungarian study of 121 unrelated focal-dystonia patients—74 CD and 47 blepharospasm—a 30-gene panel identified 209 heterozygous variants in 24 genes. Nine variants were judged clinically/genetically relevant, yielding 7.4%, although six were VUS and no functional testing was performed. Relevant variants occurred almost exclusively in CD and disproportionately in earlier-onset cases (mean onset 31.6 years). (salamon2023geneticscreeningof pages 1-2, salamon2023geneticscreeningof pages 5-6)

Reported CD-associated candidates included ANO3 c.2276-6T>C, CIZ1 c.1820A>G (p.Glu607Gly), KCNN2 c.1625G>A (p.Arg542Gln), KMT2B c.3136C>T (p.Arg1046Cys), and VPS16 c.1370T>C (p.Leu457Pro). These were chiefly VUS and should not be entered as established pathogenic variants without updated ClinVar/ClinGen review, segregation, population-frequency evaluation, and functional evidence. (salamon2023geneticscreeningof pages 5-6)

The best-characterized inherited forms are generally germline, with autosomal-dominant inheritance and incomplete penetrance common among isolated dystonias. Variable expressivity is substantial. Somatic mosaicism, anticipation, and recurrent chromosomal abnormalities are not recognized defining features of ordinary CD. No robust CD-specific modifier gene or clinically validated epigenetic signature is established. Population allele frequencies must be obtained variant-by-variant from the current gnomAD release; rare-disease pathogenic variants are generally expected to be absent or extremely rare, but no frequency should be assigned from disease reports alone.

5. Environmental and lifestyle information

The evidence for environmental causation in idiopathic CD is weaker than the evidence for age, sex, and genetic susceptibility. Clinicians should document dopamine-receptor-blocking drug exposure, neck/peripheral trauma, structural CNS injury, occupational repetitive activity, toxins, and infections, but distinguish temporal association from causality. Acute or subacute focal dystonia is atypical for ordinary idiopathic CD and raises concern for drug-induced, structural, metabolic, or autoimmune disease. There is no validated diet, exercise regimen, smoking pattern, alcohol exposure, pollution exposure, radiation source, or pathogen that specifically causes or prevents typical CD.

6. Mechanism and pathophysiology

The prevailing view is a distributed network disorder, not a primary cervical-muscle disease and not solely a basal-ganglia disorder. The implicated network comprises cerebral sensorimotor cortex, striatum and pallidum, thalamus, cerebellum, and brainstem. Core physiological abnormalities are impaired sensorimotor integration, deficient inhibition at cortical, basal-ganglia, brainstem, and spinal levels, maladaptive plasticity, and faulty motor “gating.” The causal chain proposed for idiopathic CD is: inherited/developmental susceptibility plus incompletely defined environmental or physiological triggers → altered synaptic signaling and plasticity in basal-ganglia–cerebellar–thalamo–cortical circuits → reduced surround inhibition and poor suppression of competing motor programs → simultaneous agonist/antagonist and overflow muscle activation → patterned head posture, tremor, and pain. (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2, thomsen2024geneticsandpathogenesis pages 1-2)

Molecular groupings include neurodevelopmental transcription (KMT2B, THAP1), calcium homeostasis (ANO3, HPCA), striatal dopamine/cAMP signaling (GNAL), endoplasmic-reticulum stress (TOR1A, EIF2AK2, PRKRA), and autophagy/lysosomal trafficking (VPS16). These pathways derive mainly from genetic dystonia rather than common idiopathic CD, but may expose convergent therapeutic mechanisms. (thomsen2024geneticsandpathogenesis pages 1-2)

Rodent work supports abnormal dopamine–acetylcholine balance, glutamatergic transmission, receptor trafficking, and corticostriatal plasticity. In DYT-TOR1A models, D2-receptor activation can paradoxically excite striatal cholinergic interneurons, increasing acetylcholine and impairing corticostriatal long-term depression/depotentiation. Cerebellar Purkinje-cell and deep-nuclear firing abnormalities also correlate with dystonic movements. (wilson2013animalmodelsfor pages 4-5, atiallah2023synapticdysfunctionin pages 4-5, atiallah2023synapticdysfunctionin pages 1-2)

Suggested annotations are GO: synaptic signaling; regulation of synaptic plasticity; long-term synaptic depression; dopamine-receptor signaling; cholinergic synaptic transmission; calcium-ion homeostasis; response to ER stress; autophagy. Suggested cell types are striatal medium spiny/projection neuron, striatal cholinergic interneuron, cerebellar Purkinje cell, deep cerebellar nuclear neuron, thalamic neuron, and cortical pyramidal neuron. There is no validated CD-specific immune, metabolomic, lipidomic, methylomic, proteomic, single-cell, spatial-transcriptomic, or multi-omic diagnostic signature. Available advanced-omics evidence is mostly from monogenic models and remains investigational.

7. Anatomical structures affected

At the effector level, CD affects skeletal muscles of the neck and upper shoulder girdle, commonly including sternocleidomastoid, splenius capitis/cervicis, semispinalis, levator scapulae, trapezius, scalene, and deep suboccipital muscles. Activation is usually asymmetric but can be bilateral. Secondary effects include cervical pain, restricted mobility, degenerative musculoskeletal strain, and occasionally dysphagia.

At the nervous-system level, implicated sites are motor/premotor and somatosensory cortex, striatum, globus pallidus, thalamus, cerebellar cortex/deep nuclei, and brainstem. Suggested UBERON annotations are neck region, skeletal muscle of neck, cerebral cortex, basal ganglion, globus pallidus, thalamus, cerebellum, brainstem. Relevant subcellular compartments in genetic forms include ER/nuclear envelope (torsinA), synapse/presynaptic vesicle machinery, plasma-membrane signaling complexes, and lysosome/autophagosome. (atiallah2023synapticdysfunctionin pages 4-5, bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2)

8. Temporal development

Typical onset is insidious in middle adulthood, often initially intermittent and aggravated by action, stress, fatigue, or particular head positions. Symptoms commonly evolve over months to several years before becoming relatively stable, although day-to-day fluctuation persists. CD is generally chronic and lifelong. Spread is less common than in blepharospasm but may produce craniocervical or other segmental dystonia. Spontaneous remissions are reported clinically but are uncommon and may relapse; no evidence supports a predictable critical window for disease prevention. Early specialist diagnosis is nevertheless valuable because prolonged diagnostic delay extends pain, disability, and ineffective care. (salamon2023geneticscreeningof pages 1-2, zhao2024longtermfollowupof pages 1-2)

9. Inheritance and population epidemiology

Dystonia was historically classified as rare, but recent estimates cited in the 2024 review placed isolated dystonia overall at 30.9–52.7 per 100,000; true prevalence may be higher because of underdiagnosis and misdiagnosis. These are not CD-specific prevalence estimates. (thomsen2024geneticsandpathogenesis pages 2-4)

In the Italian registry, 848/1,701 patients had cervical involvement at final examination; 558 were women and 290 men. Neck pain prevalence did not differ materially by sex. The study also supports female predominance in craniocervical dystonia, while task-specific upper-limb dystonia showed male predominance. (velucci2024doessexinfluence pages 2-3)

Geographic estimates vary with ascertainment and ancestry. A 2024 craniocervical-dystonia report cited a roughly threefold higher CD incidence among White than Asian populations, but this secondary statement requires confirmation in the original multiethnic epidemiologic study before population-risk annotation. (zhao2024longtermfollowupof pages 1-2)

Most CD is sporadic/multifactorial. Monogenic cases can be autosomal dominant with reduced penetrance and variable expressivity; recessive and other inheritance patterns occur in broader dystonia syndromes. Founder effects, carrier frequency, anticipation, germline mosaicism, and consanguinity are gene- and variant-specific rather than general CD properties.

10. Diagnosis

Diagnosis is clinical and should be made by a clinician experienced in movement disorders. Examination establishes the posture/movement pattern, active muscles, tremor, pain, sensory tricks, task dependence, range of motion, and spread. Standardized scales include TWSTRS, Tsui score, Cervical Dystonia Impact Profile, and pain/quality-of-life measures. Surface or needle EMG and ultrasound help identify injection targets but are not standalone diagnostic biomarkers.

MRI or CT is appropriate when onset or examination suggests a structural cause. In the Italian registry, all patients underwent brain MRI or CT, with Wilson-disease testing and testing of TOR1A, THAP1, ANO3, and GNAL when appropriate. (velucci2024doessexinfluence pages 1-2)

There is no diagnostic blood, CSF, tissue, electrophysiologic, imaging, proteomic, metabolomic, or liquid-biopsy biomarker for idiopathic CD. Genetic testing is highest yield with onset before approximately 20–30 years, positive family history, generalized/segmental spread, developmental or additional neurologic features, or an atypical course. A dystonia panel is a reasonable first test; WES/WGS is appropriate when panel testing is unrevealing and suspicion remains high. CMA, karyotype, FISH, mitochondrial testing, and repeat-expansion testing are not routine for typical adult-onset isolated CD but may be indicated by syndromic features. The 2023 focal-dystonia cohort found no clear WES-yield advantage over a curated panel in its small WES subset. (salamon2023geneticscreeningof pages 5-6)

Differential diagnoses include essential or dystonic tremor, Parkinsonian anterocollis, tics, functional dystonia, congenital/orthopedic torticollis, cervical radiculopathy, atlantoaxial disease, drug-induced/tardive dystonia, Wilson disease, structural lesions, neurodegenerative or metabolic dystonia, autoimmune encephalitis, and craniocervical dystonia/Meige syndrome. Population or newborn screening is not recommended. Cascade testing is appropriate only after a clearly pathogenic familial variant is established.

11. Outcome and prognosis

CD generally does not shorten life expectancy, and disease-specific survival statistics are not clinically applicable. Its burden is morbidity: pain, impaired head control, tremor, sleep disturbance, reduced employment and driving, anxiety/depression, social isolation, and treatment burden. Fixed postures, orthopedic strain, dysphagia, and treatment-related neck weakness are possible complications.

Prognosis is heterogeneous. Many patients obtain meaningful symptomatic control with individualized botulinum-neurotoxin treatment, but treatment must be repeated. Motor response does not guarantee resolution of pain, mood, sleep, or social disability. No validated molecular prognostic biomarker predicts spread, remission, toxin response, or DBS response.

12. Treatment and recent developments

Botulinum neurotoxin

Intramuscular botulinum neurotoxin is the standard first-line treatment. BoNT/A products include onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and the longer-acting daxibotulinumtoxinA-lanm; rimabotulinumtoxinB is a BoNT/B option. Products are not dose-unit interchangeable. The toxin cleaves SNARE proteins in cholinergic terminals, reducing acetylcholine release and excessive muscle contraction. Muscle selection should follow the observed posture and collum–caput pattern, with ultrasound and/or EMG guidance for deep or difficult targets. (salamon2023geneticscreeningof pages 1-2)

Common adverse effects are dysphagia, neck weakness, local pain, dry mouth, flu-like symptoms, and excessive weakness. Apparent nonresponse should prompt reassessment of diagnosis, muscle selection, dose, guidance, injection interval, fixed contracture, and rarely neutralizing antibodies.

A 2024 review documented continued formulation development, including prabotulinumtoxinA/ABP-450 (phase 2), neubotulinumtoxinA (phase 3), and A2NTX (phase 1) for CD at the time reviewed. These pipeline statuses require confirmation against the current trial registry. DOI: https://doi.org/10.3390/toxins16060261; published June 2024. (rasettiescargueil2024embracingtheversatility pages 9-10)

Suggested NCIt concepts: Botulinum Toxin Type A, Botulinum Toxin Type B, intramuscular injection, electromyography-guided injection, ultrasonography-guided injection.

Oral, supportive, and rehabilitative treatment

Oral drugs are generally adjunctive and have weaker evidence than BoNT: trihexyphenidyl, clonazepam or other benzodiazepines, baclofen, and selected dopamine-modulating agents. Treatment should address pain, depression/anxiety, sleep, and occupational limitations. Physical therapy emphasizing sensorimotor retraining, posture, active exercise, and home programs may complement BoNT; forceful passive manipulation should be avoided. Occupational, psychological, and pain-management support are often appropriate.

Deep-brain stimulation and surgery

Bilateral globus pallidus internus DBS is an option for severe medically refractory CD/segmental craniocervical dystonia. In a 2024 retrospective series of 24 refractory craniocervical-dystonia patients, mean BFMDRS motor score improved 55.3% at six months and 56.6% at a mean 37.5-month follow-up; six patients (25%) had less than 30% improvement, demonstrating important response variability. DOI: https://doi.org/10.3171/2024.3.FOCUS23890; published June 2024. (zhao2024longtermfollowupof pages 5-6, zhao2024longtermfollowupof pages 1-2)

Selective peripheral denervation is now less common but may be considered at specialized centers. Gene, cell, RNA, and immune therapies are not established for idiopathic CD. Genotype-directed treatment applies mainly to a minority of broader dystonia syndromes—for example levodopa-responsive GCH1 disease—not to routine adult-onset CD.

13. Prevention

There is no proven primary prevention, vaccine, prophylactic drug, population screening program, or validated behavioral intervention for idiopathic CD. Avoiding unnecessary dopamine-receptor-blocking drugs may reduce tardive dystonia risk but does not prevent idiopathic CD. Secondary prevention consists of prompt recognition of patterned dystonia and investigation of atypical or treatable acquired causes. Tertiary prevention includes optimized BoNT treatment, rehabilitation, pain and psychiatric care, swallowing monitoring, avoidance of fixed contractures, and DBS evaluation where appropriate. Genetic counseling is indicated for pathogenic variants or strong familial disease; prenatal or preimplantation testing is relevant only after a well-established familial pathogenic variant and individualized counseling.

14. Other species and naturally occurring disease

No well-established naturally occurring veterinary disorder is a direct homolog of common adult-onset idiopathic human CD. Animals may display torticollis from vestibular, infectious, toxic, traumatic, or structural disease, but this is not equivalent to human cervical dystonia. There is no zoonotic transmission. Orthologous dystonia genes are highly conserved across mammals, enabling mechanistic models, but veterinary breed-specific and VBO annotations should not be assigned without OMIA/VetCompass confirmation.

15. Model organisms

Models include genetic knock-in/knockout/conditional mice for Tor1a, Thap1, Gnal, Sgce, pharmacologic and lesion models in mice/rats, and toxin or pallidal-manipulation models in nonhuman primates. Dystonic rats carrying Caytaxin defects and tottering mice with Cacna1a/Cav2.1 dysfunction exhibit abnormal Purkinje/deep-cerebellar-nuclear firing correlated with dystonic movements. Cerebellar lesion or inactivation can suppress dystonia in several models, while targeted glutamatergic stimulation can provoke it. (wilson2013animalmodelsfor pages 4-5)

Modern optogenetic and chemogenetic studies permit cell- and circuit-specific perturbation of basal-ganglia and cerebellar pathways. A 2024 review concluded that both systems are pathologically altered but emphasized that exact causal cell populations remain unresolved. DOI: https://doi.org/10.3389/dyst.2024.11793; published February 19, 2024. (rauschenberger2024unravelingdystoniacircuitry pages 1-2)

These models have construct validity for particular monogenic dystonias and are useful for synaptic physiology, developmental timing, circuit mapping, DBS mechanisms, and target discovery. Their principal limitation is that many do not reproduce spontaneous adult-onset focal neck dystonia; some show only subtle physiology or generalized dystonia-like movements. Findings therefore support convergent dystonia mechanisms but cannot automatically be treated as CD-specific human biology.

Overall expert interpretation

Cervical dystonia is best represented in a knowledge base as a complex, predominantly sporadic adult-onset focal network disorder with occasional monogenic causes. Its defining data layer should prioritize clinical phenomenology, neck pain, tremor, sensory tricks, disability, and treatment response. Genetic entries should carry evidence-level qualifiers: THAP1, GNAL, and ANO3 are credible causes of inherited dystonia with cervical involvement, whereas many recently observed focal-dystonia variants remain VUS. The most mature real-world intervention is individualized, repeatedly administered botulinum neurotoxin; GPi-DBS is effective for selected refractory disease but has meaningful nonresponse and durability uncertainty. The largest gaps are validated biomarkers, CD-specific multi-omics, firmly replicated gene–environment interactions, preventive strategies, and models that faithfully reproduce adult-onset focal cervical disease. (thomsen2024geneticsandpathogenesis pages 1-2, salamon2023geneticscreeningof pages 5-6, zhao2024longtermfollowupof pages 1-2)

References

(thomsen2024geneticsandpathogenesis pages 1-2): Mirja Thomsen, Lara M. Lange, Michael Zech, and Katja Lohmann. Genetics and pathogenesis of dystonia. Annual Review of Pathology: Mechanisms of Disease, 19:99-131, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-110756, doi:10.1146/annurev-pathmechdis-051122-110756. This article has 117 citations and is from a domain leading peer-reviewed journal.
(thomsen2024geneticsandpathogenesis pages 2-4): Mirja Thomsen, Lara M. Lange, Michael Zech, and Katja Lohmann. Genetics and pathogenesis of dystonia. Annual Review of Pathology: Mechanisms of Disease, 19:99-131, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-110756, doi:10.1146/annurev-pathmechdis-051122-110756. This article has 117 citations and is from a domain leading peer-reviewed journal.
(velucci2024doessexinfluence pages 1-2): Vittorio Velucci, Sarah Idrissi, R. Pellicciari, Marcello Esposito, Assunta Trinchillo, D. Belvisi, Giovanni Fabbrini, G. Ferrazzano, C. Terranova, P. Girlanda, Giovanni Majorana, V. Rizzo, Francesco Bono, Giovanni Idone, Vincenzo Laterza, L. Avanzino, F. di Biasio, R. Marchese, A. Castagna, M. Ramella, C. Lettieri, S. Rinaldo, M. C. Altavista, Luigi Polidori, L. Bertolasi, M. C. Tozzi, R. Erro, P. Barone, Pierangelo Barbero, R. Ceravolo, M. Mascia, Tommaso Ercoli, A. Muroni, C. Artusi, M. Zibetti, C. Scaglione, A. Bentivoglio, Maria Sofia Cotelli, L. Magistrelli, G. Cossu, A. Albanese, G. Squintani, T. Schirinzi, A. Gigante, L. Maderna, R. Eleopra, Antonio Pisani, D. Cassano, M. Romano, Marina Rizzo, A. Berardelli, and G. Defazio. Does sex influence the natural history of idiopathic adult-onset dystonia? Journal of Neurology, Neurosurgery, and Psychiatry, 95:784-790, Mar 2024. URL: https://doi.org/10.1136/jnnp-2023-332927, doi:10.1136/jnnp-2023-332927. This article has 12 citations.
(velucci2024doessexinfluence pages 2-3): Vittorio Velucci, Sarah Idrissi, R. Pellicciari, Marcello Esposito, Assunta Trinchillo, D. Belvisi, Giovanni Fabbrini, G. Ferrazzano, C. Terranova, P. Girlanda, Giovanni Majorana, V. Rizzo, Francesco Bono, Giovanni Idone, Vincenzo Laterza, L. Avanzino, F. di Biasio, R. Marchese, A. Castagna, M. Ramella, C. Lettieri, S. Rinaldo, M. C. Altavista, Luigi Polidori, L. Bertolasi, M. C. Tozzi, R. Erro, P. Barone, Pierangelo Barbero, R. Ceravolo, M. Mascia, Tommaso Ercoli, A. Muroni, C. Artusi, M. Zibetti, C. Scaglione, A. Bentivoglio, Maria Sofia Cotelli, L. Magistrelli, G. Cossu, A. Albanese, G. Squintani, T. Schirinzi, A. Gigante, L. Maderna, R. Eleopra, Antonio Pisani, D. Cassano, M. Romano, Marina Rizzo, A. Berardelli, and G. Defazio. Does sex influence the natural history of idiopathic adult-onset dystonia? Journal of Neurology, Neurosurgery, and Psychiatry, 95:784-790, Mar 2024. URL: https://doi.org/10.1136/jnnp-2023-332927, doi:10.1136/jnnp-2023-332927. This article has 12 citations.
(salamon2023geneticscreeningof pages 1-2): András Salamon, Zsófia Flóra Nagy, Margit Pál, Máté Szabó, Ádám Csősz, László Szpisjak, Gabriella Gárdián, Dénes Zádori, Márta Széll, and Péter Klivényi. Genetic screening of a hungarian cohort with focal dystonia identified several novel putative pathogenic gene variants. International Journal of Molecular Sciences, 24:10745, Jun 2023. URL: https://doi.org/10.3390/ijms241310745, doi:10.3390/ijms241310745. This article has 8 citations.
(kuyper2011nonmotormanifestationsof pages 4-5): Daniel J. Kuyper, Veronica Parra, Shanae Aerts, Michael S. Okun, and Benzi M. Kluger. Nonmotor manifestations of dystonia: a systematic review. Movement Disorders, 26:1206-1217, Jun 2011. URL: https://doi.org/10.1002/mds.23709, doi:10.1002/mds.23709. This article has 264 citations and is from a highest quality peer-reviewed journal.
(bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2): Norbert Brüggemann. Contemporary functional neuroanatomy and pathophysiology of dystonia. Journal of Neural Transmission, 128:499-508, Jan 2021. URL: https://doi.org/10.1007/s00702-021-02299-y, doi:10.1007/s00702-021-02299-y. This article has 77 citations and is from a peer-reviewed journal.
(salamon2023geneticscreeningof pages 5-6): András Salamon, Zsófia Flóra Nagy, Margit Pál, Máté Szabó, Ádám Csősz, László Szpisjak, Gabriella Gárdián, Dénes Zádori, Márta Széll, and Péter Klivényi. Genetic screening of a hungarian cohort with focal dystonia identified several novel putative pathogenic gene variants. International Journal of Molecular Sciences, 24:10745, Jun 2023. URL: https://doi.org/10.3390/ijms241310745, doi:10.3390/ijms241310745. This article has 8 citations.
(rauschenberger2024unravelingdystoniacircuitry pages 1-2): Lisa Rauschenberger and Chi Wang Ip. Unraveling dystonia circuitry in rodent models using novel neuromodulation techniques. Dystonia, Feb 2024. URL: https://doi.org/10.3389/dyst.2024.11793, doi:10.3389/dyst.2024.11793. This article has 2 citations.
(atiallah2023synapticdysfunctionin pages 1-2): Ilham El Atiallah, Paola Bonsi, Annalisa Tassone, Giuseppina Martella, Gerardo Biella, Antonio N. Castagno, Antonio Pisani, and Giulia Ponterio. Synaptic dysfunction in dystonia: update from experimental models. Current Neuropharmacology, 21:2310-2322, Nov 2023. URL: https://doi.org/10.2174/1570159x21666230718100156, doi:10.2174/1570159x21666230718100156. This article has 11 citations and is from a peer-reviewed journal.
(atiallah2023synapticdysfunctionin pages 4-5): Ilham El Atiallah, Paola Bonsi, Annalisa Tassone, Giuseppina Martella, Gerardo Biella, Antonio N. Castagno, Antonio Pisani, and Giulia Ponterio. Synaptic dysfunction in dystonia: update from experimental models. Current Neuropharmacology, 21:2310-2322, Nov 2023. URL: https://doi.org/10.2174/1570159x21666230718100156, doi:10.2174/1570159x21666230718100156. This article has 11 citations and is from a peer-reviewed journal.
(rasettiescargueil2024embracingtheversatility pages 9-10): Christine Rasetti-Escargueil and Stefano Palea. Embracing the versatility of botulinum neurotoxins in conventional and new therapeutic applications. Toxins, 16:261, Jun 2024. URL: https://doi.org/10.3390/toxins16060261, doi:10.3390/toxins16060261. This article has 37 citations.
(zhao2024longtermfollowupof pages 1-2): Zhuoling Zhao, Zhiwei Ren, Yongsheng Hu, Kaijia Yu, Fangzhao Yin, Jianyu Li, and Guojun Zhang. Long-term follow-up of pallidal deep brain stimulation for craniocervical dystonia: is the globus pallidus internus the best target? Neurosurgical focus, 56 6:E16, Jun 2024. URL: https://doi.org/10.3171/2024.3.focus23890, doi:10.3171/2024.3.focus23890. This article has 2 citations.
(zhao2024longtermfollowupof pages 5-6): Zhuoling Zhao, Zhiwei Ren, Yongsheng Hu, Kaijia Yu, Fangzhao Yin, Jianyu Li, and Guojun Zhang. Long-term follow-up of pallidal deep brain stimulation for craniocervical dystonia: is the globus pallidus internus the best target? Neurosurgical focus, 56 6:E16, Jun 2024. URL: https://doi.org/10.3171/2024.3.focus23890, doi:10.3171/2024.3.focus23890. This article has 2 citations.
(wilson2013animalmodelsfor pages 4-5): Bethany K. Wilson and Ellen J. Hess. Animal models for dystonia. Movement Disorders, 28:982-989, Jun 2013. URL: https://doi.org/10.1002/mds.25526, doi:10.1002/mds.25526. This article has 84 citations and is from a highest quality peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	12
Resolved	12
Unresolved (possible confabulation)	0
Unverifiable	0

All extracted references resolved successfully.

Cervical Dystonia

Ask OpenScientist

OpenScientist Report

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Prevalence

Differential Diagnoses

Source YAML

References & Deep Research

Deep Research

Cervical Dystonia: Disease-Characteristics Research Report

Scope and evidence note

1. Disease information

2. Etiology, risk, protective factors, and gene–environment interaction

3. Phenotypes and quality-of-life effects

4. Genetic and molecular information

5. Environmental and lifestyle information

6. Mechanism and pathophysiology

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population epidemiology

10. Diagnosis

11. Outcome and prognosis

12. Treatment and recent developments

Botulinum neurotoxin

Oral, supportive, and rehabilitative treatment

Deep-brain stimulation and surgery

13. Prevention

14. Other species and naturally occurring disease

15. Model organisms

Overall expert interpretation

Artifacts

Reference Validation

Domain	Key finding/statistic	Evidence type	Ontology suggestions	Source / date / DOI
Definition / disease scope	Cervical dystonia (CD) is an adult-onset focal dystonia affecting the neck, characterized by sustained or intermittent muscle contractions causing abnormal head/neck postures and movements; sensory trick (geste antagoniste) is a supportive sign. General dystonia finding: dystonia is defined as abnormal repetitive movements/postures caused by sustained or intermittent muscle contractions; touching the chin can reduce symptoms in CD (thomsen2024geneticsandpathogenesis pages 1-2).	Expert review; clinical classification	MONDO: cervical dystonia if available; MeSH: Dystonic Disorders; HPO: HP:0001332 Dystonia, HP:0031987 Abnormal head posture, HP:0000496 Abnormality of movement; UBERON: neck region	Thomsen et al., Annu Rev Pathol 2024;19:99-131. Published online 2023-09-22. DOI: 10.1146/annurev-pathmechdis-051122-110756 (thomsen2024geneticsandpathogenesis pages 1-2)
Key identifiers / classification	General dystonia finding: consensus classification uses axis I (age at onset, body distribution, temporal pattern, associated features) and axis II (etiology). Focal dystonia = one body region affected; late adulthood onset >40 years (thomsen2024geneticsandpathogenesis pages 2-4).	Expert consensus review	HPO: HP:0003577 Adult onset, HP:0001332 Dystonia; NCIT: focal dystonia	Thomsen et al., Annu Rev Pathol 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756 (thomsen2024geneticsandpathogenesis pages 2-4)
Epidemiology	General isolated dystonia finding: prevalence estimated at 52.7/100,000 or 30.9/100,000; true prevalence may be higher because many cases remain un-/misdiagnosed; higher prevalence in females for most subforms (thomsen2024geneticsandpathogenesis pages 2-4, thomsen2024geneticsandpathogenesis pages 1-2).	Epidemiology summarized in review	NCIT: Prevalence; HPO: not applicable	Thomsen et al., Annu Rev Pathol 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756 (thomsen2024geneticsandpathogenesis pages 2-4, thomsen2024geneticsandpathogenesis pages 1-2)
Epidemiology / sex distribution	In a 1,701-patient Italian idiopathic adult-onset dystonia registry, cervical dystonia was present in 848/1701 at last exam; female:male ratio for CD 1.9 (95% CI 1.8-2.1). At onset, CD accounted for 681/1574 focal onsets, female:male ratio 1.9 (1.7-2.0) (velucci2024doessexinfluence pages 1-2, velucci2024doessexinfluence pages 2-3).	Large human registry	HPO: HP:0001332 Dystonia; NCIT: Female, Male	Velucci et al., J Neurol Neurosurg Psychiatry 2024;95:784-790. March 2024. DOI: 10.1136/jnnp-2023-332927 (velucci2024doessexinfluence pages 1-2, velucci2024doessexinfluence pages 2-3)
Phenotype / onset	CD usually begins between 45-50 years; symptoms include dystonic neck posture plus, in some patients, dystonic tremor and pain; risk of spread to other body parts is described as very low in one focal-dystonia review/cohort summary (salamon2023geneticscreeningof pages 1-2).	Review with focal-dystonia cohort context	HPO: HP:0002418 Torticollis, HP:0001336 Tremor, HP:0012531 Neck pain, HP:0002829 Arthralgia/pain if needed	Salamon et al., Int J Mol Sci 2023;24:10745. 2023-06-28. DOI: 10.3390/ijms241310745 (salamon2023geneticscreeningof pages 1-2)
Phenotype / associated features	In the 1,701-patient registry, sensory trick occurred in 483/1701 (28.4%), tremor in 516/1701 (30.3%); among CD cases, neck pain occurred in 488/848 (57.5%) with similar frequency by sex (58.1% women vs 56.6% men) (velucci2024doessexinfluence pages 2-3).	Large human registry	HPO: HP:0003394 Sensory trick (suggested), HP:0001336 Tremor, HP:0012531 Neck pain	Velucci et al., J Neurol Neurosurg Psychiatry 2024. DOI: 10.1136/jnnp-2023-332927 (velucci2024doessexinfluence pages 2-3)
Non-motor / quality of life	General dystonia with CD-relevant data: pain prevalence in CD ranges 67%-75% in older systematic review data; a study of 116 patients with spasmodic torticollis found 71% lifetime social phobia, correlated with body image/maladaptive attitude rather than objective severity (kuyper2011nonmotormanifestationsof pages 4-5).	Systematic review of non-motor manifestations	HPO: HP:0012531 Neck pain, HP:0000739 Anxiety, HP:0000729 Depression, HP:0000705 Social phobia (suggested)	Kuyper et al., Movement Disorders 2011;26:1206-1217. June 2011. DOI: 10.1002/mds.23709 (kuyper2011nonmotormanifestationsof pages 4-5)
Etiology	Most adult-onset isolated/CD cases are idiopathic/sporadic and likely multifactorial; monogenic causes are uncommon in isolated focal dystonia, and gene-environment interaction is suspected in sporadic cases (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2, salamon2023geneticscreeningof pages 5-6).	Review; focal-dystonia sequencing study	MONDO: idiopathic isolated dystonia; HPO: HP:0001332 Dystonia	Brüggemann, J Neural Transm 2021;128:499-508. DOI: 10.1007/s00702-021-02299-y; Salamon et al., Int J Mol Sci 2023. DOI: 10.3390/ijms241310745 (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2, salamon2023geneticscreeningof pages 5-6)
Genetic factors	In focal dystonia, genes most often implicated in CD screening studies include THAP1, CIZ1, GNAL, ANO3; in a Hungarian cohort of 121 focal dystonia patients (74 CD), 30-gene NGS found 209 heterozygous variants in 24 genes, with 9 clinically/genetically relevant variants total and overall diagnostic yield 7.4% (salamon2023geneticscreeningof pages 1-2, salamon2023geneticscreeningof pages 5-6).	Human sequencing cohort	HGNC genes: THAP1, CIZ1, GNAL, ANO3, KMT2B, VPS16, KCNN2; NCIT: Next-Generation Sequencing	Salamon et al., Int J Mol Sci 2023;24:10745. 2023-06-28. DOI: 10.3390/ijms241310745 (salamon2023geneticscreeningof pages 1-2, salamon2023geneticscreeningof pages 5-6)
Pathogenic / candidate variants	CD-relevant variants in the Hungarian cohort included ANO3 c.2276-6T>C (splice region), CIZ1 c.1820A>G p.Glu607Gly, KCNN2 c.1625G>A p.Arg542Gln, KMT2B c.3136C>T p.Arg1046Cys, and VPS16 c.1370T>C p.Leu457Pro; most relevant variants occurred in earlier-onset cases (mean onset 31.6 years) (salamon2023geneticscreeningof pages 5-6).	Human sequencing cohort	HGVS variant notation; HPO: HP:0003577 Adult onset, HP:0003621 Juvenile onset if early; NCIT: Variant of Uncertain Significance, Likely Pathogenic Variant	Salamon et al., Int J Mol Sci 2023. DOI: 10.3390/ijms241310745 (salamon2023geneticscreeningof pages 5-6)
Diagnostic genetics strategy	For focal dystonia/CD, detailed genetic work-up is most justified when there is early onset, family history, or additional neurological/non-neurological features; the 2023 cohort recommended targeted gene panels when budget is limited, with WES not clearly superior for yield in their sample (salamon2023geneticscreeningof pages 5-6).	Human cohort interpretation / expert recommendation	NCIT: Gene Panel Testing, Whole Exome Sequencing	Salamon et al., Int J Mol Sci 2023. DOI: 10.3390/ijms241310745 (salamon2023geneticscreeningof pages 5-6)
Mechanisms / systems neuroscience	General dystonia finding with relevance to CD: dystonia is a network disorder involving basal ganglia, cerebellum, thalamus, and cortex rather than only basal ganglia; impaired sensorimotor integration, reduced inhibition, and maladaptive plasticity are core mechanisms (thomsen2024geneticsandpathogenesis pages 1-2, bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2, rauschenberger2024unravelingdystoniacircuitry pages 1-2).	Expert review; mechanistic review	GO: synaptic signaling, regulation of neurotransmitter levels, motor control; UBERON: basal ganglion, cerebellum, thalamus, cerebral cortex; CL: Purkinje cell, striatal medium spiny neuron, cholinergic interneuron	Thomsen et al., Annu Rev Pathol 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756; Brüggemann, J Neural Transm 2021. DOI: 10.1007/s00702-021-02299-y; Rauschenberger & Ip, Dystonia 2024. DOI: 10.3389/dyst.2024.11793 (thomsen2024geneticsandpathogenesis pages 1-2, bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2, rauschenberger2024unravelingdystoniacircuitry pages 1-2)
Mechanisms / molecular pathways	General dystonia finding: implicated pathways include gene transcription during neurodevelopment (e.g., KMT2B, THAP1), calcium homeostasis (ANO3, HPCA), striatal dopamine signaling (GNAL), ER stress response (EIF2AK2, PRKRA, TOR1A), and autophagy/lysosomal trafficking (VPS16) (thomsen2024geneticsandpathogenesis pages 1-2).	Expert molecular review	GO: regulation of transcription, calcium ion homeostasis, dopamine receptor signaling pathway, response to endoplasmic reticulum stress, autophagy; CL: striatal neuron	Thomsen et al., Annu Rev Pathol 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756 (thomsen2024geneticsandpathogenesis pages 1-2)
Mechanisms / synaptic physiology	General dystonia finding: rodent models support abnormal neurotransmitter signaling, receptor trafficking, and synaptic plasticity in basal ganglia and cerebellum as common hallmarks. In DYT-TOR1A models, altered dopamine-acetylcholine balance disrupts corticostriatal LTD/depotentiation; D2 receptor activation paradoxically excites cholinergic interneurons (atiallah2023synapticdysfunctionin pages 1-2, atiallah2023synapticdysfunctionin pages 4-5).	Rodent/mechanistic review	GO: synaptic plasticity, long-term synaptic depression, dopaminergic signaling, cholinergic signaling; CL: cholinergic interneuron, Purkinje cell, deep cerebellar nucleus neuron	El Atiallah et al., Curr Neuropharmacol 2023;21:2310-2322. DOI: 10.2174/1570159X21666230718100156 (atiallah2023synapticdysfunctionin pages 1-2, atiallah2023synapticdysfunctionin pages 4-5)
Anatomy affected	Primary clinically affected structure is the cervical musculature/neck region; biologically implicated CNS nodes include cortex, basal ganglia, thalamus, cerebellum, and brainstem. CD may occur at rest, unlike some task-specific dystonias (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2).	Review	UBERON: neck, skeletal muscle of neck, cerebellum, thalamus, basal ganglion, cerebral cortex; CL: Purkinje cell, medium spiny neuron	Brüggemann, J Neural Transm 2021. DOI: 10.1007/s00702-021-02299-y (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2)
Diagnosis / clinical work-up	CD is primarily a clinical diagnosis by expert examination; work-up for idiopathic adult-onset dystonia in the Italian registry included brain MRI or CT to exclude structural causes and testing for Wilson disease and common monogenic dystonia variants (TOR1A, THAP1, ANO3, GNAL) as appropriate (velucci2024doessexinfluence pages 1-2).	Large registry / clinical practice description	NCIT: Magnetic Resonance Imaging, Computed Tomography, Genetic Testing; HPO: HP:0001332 Dystonia	Velucci et al., J Neurol Neurosurg Psychiatry 2024. DOI: 10.1136/jnnp-2023-332927 (velucci2024doessexinfluence pages 1-2)
Differential diagnosis	Important exclusions include structural/acquired dystonia, Wilson disease, and monogenic non-degenerative dystonias; expert reviews also note combined and complex dystonias, and autoimmune causes should be considered in subacute focal/segmental craniocervical presentations.	Registry protocol; expert review	MONDO: Wilson disease; NCIT: Differential Diagnosis	Velucci et al., J Neurol Neurosurg Psychiatry 2024. DOI: 10.1136/jnnp-2023-332927; Thomsen et al., Annu Rev Pathol 2024. DOI: 10.1146/annurev-pathmechdis-051122-110756 (velucci2024doessexinfluence pages 1-2, thomsen2024geneticsandpathogenesis pages 1-2)
Treatment / first-line	Botulinum neurotoxin (BoNT) is standard symptomatic treatment for CD; in the focal-dystonia cohort summary, BoNT therapy (types A and B) was described as essential for proper treatment, with muscle selection aided by ultrasound and/or EMG and the collum-caput concept (salamon2023geneticscreeningof pages 1-2).	Clinical review / implementation description	NCIT: Botulinum Toxin Type A, Botulinum Toxin Type B, Electromyography, Ultrasonography	Salamon et al., Int J Mol Sci 2023. DOI: 10.3390/ijms241310745 (salamon2023geneticscreeningof pages 1-2)
Treatment / BoNT landscape	General therapeutic context with CD-specific pipeline data: BoNTs are routinely used for CD. A 2024 toxin review lists formulations/trials including PrabotulinumtoxinA (ABP-450, phase 2, migraine/cervical dystonia), NeubotulinumtoxinA (phase 3, cervical dystonia), and A2NTX (phase 1, cervical dystonia) (rasettiescargueil2024embracingtheversatility pages 9-10).	Therapeutics review / clinical pipeline summary	NCIT: Botulinum Toxin, Clinical Trial	Rasetti-Escargueil & Palea, Toxins 2024;16:261. June 2024. DOI: 10.3390/toxins16060261 (rasettiescargueil2024embracingtheversatility pages 9-10)
Treatment / surgery	For refractory craniocervical dystonia including CD, GPi deep brain stimulation shows sustained benefit but variable durability. In a 2024 retrospective series of 24 patients, mean BFMDRS motor improved 55.3% at 6 months and 56.6% at last follow-up; 25% had poor results (<30% improvement) (zhao2024longtermfollowupof pages 1-2, zhao2024longtermfollowupof pages 5-6).	Human surgical cohort	NCIT: Deep Brain Stimulation, Globus Pallidus Internus	Zhao et al., Neurosurg Focus 2024;56(6):E16. June 2024. DOI: 10.3171/2024.3.FOCUS23890 (zhao2024longtermfollowupof pages 1-2, zhao2024longtermfollowupof pages 5-6)
Prognosis / natural history	CD is usually chronic. In idiopathic adult-onset forms, spread and phenotype vary by body region; in craniocervical dystonia, symptoms often begin with blepharospasm or CD and may spread over time. Long-term DBS benefit can fluctuate, with nonresponse or secondary worsening in a subset (zhao2024longtermfollowupof pages 1-2, zhao2024longtermfollowupof pages 5-6, salamon2023geneticscreeningof pages 1-2).	Human cohort; review	HPO: HP:0003676 Progressive course; NCIT: Disease Progression	Zhao et al., Neurosurg Focus 2024. DOI: 10.3171/2024.3.FOCUS23890; Salamon et al., Int J Mol Sci 2023. DOI: 10.3390/ijms241310745 (zhao2024longtermfollowupof pages 1-2, zhao2024longtermfollowupof pages 5-6, salamon2023geneticscreeningof pages 1-2)
Prevention	No established primary prevention exists for idiopathic CD. Practical prevention is mainly tertiary: early recognition, optimized BoNT injection strategy, rehabilitation, and consideration of DBS in refractory disease to reduce disability and pain.	Inference from current care evidence	NCIT: Rehabilitation, Supportive Care, Deep Brain Stimulation	Supported by treatment reviews/cohorts (salamon2023geneticscreeningof pages 1-2, zhao2024longtermfollowupof pages 1-2, rasettiescargueil2024embracingtheversatility pages 9-10)
Models / animal and cellular	General dystonia model evidence: rodent and primate models implicate both basal ganglia and cerebellum. Lesion, pharmacologic, optogenetic, chemogenetic, and genetic models show that cerebellar stimulation/inactivation can induce or suppress dystonia-like movements; abnormal Purkinje-cell and deep cerebellar nucleus firing are recurrent findings (rauschenberger2024unravelingdystoniacircuitry pages 1-2, wilson2013animalmodelsfor pages 4-5, atiallah2023synapticdysfunctionin pages 4-5).	Rodent/primate experimental evidence	CL: Purkinje cell, deep cerebellar nucleus neuron, striatal projection neuron; GO: action potential, synaptic signaling	Rauschenberger & Ip, Dystonia 2024. DOI: 10.3389/dyst.2024.11793; Wilson & Hess, Mov Disord 2013. DOI: 10.1002/mds.25526; El Atiallah et al., Curr Neuropharmacol 2023. DOI: 10.2174/1570159X21666230718100156 (rauschenberger2024unravelingdystoniacircuitry pages 1-2, wilson2013animalmodelsfor pages 4-5, atiallah2023synapticdysfunctionin pages 4-5)